Search results
Is Geron Stock a Buy Following Its First New Drug Approval?
Motley Fool via Yahoo Finance· 6 hours agoThe condition affects about 60,000 Americans, with roughly 16,000 new reported cases annually....
Cancer-fighting antibodies inject chemo directly into tumor cells, upping effectiveness
NBC NEWS· 6 days agoThe approach isn’t entirely new: The first antibody drug conjugate was approved by the Food and Drug...
Valrubicin-loaded immunoliposomes: A new technology to fight hematological cancer
Medical Xpress· 2 days agoValrubicin, a lipophilic chemical molecule similar to daunorubicin, has primarily been used in the treatment of bladder cancer. An article recently published in Cell Death ...
MD Anderson Research Highlights for June 5, 2024 | Newswise
Newswise· 4 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Steps To-Marrow: Grandmother walks hundreds of miles to raise donor awareness
The Wenatchee World· 3 days agoJeana Moore, 71, is not singing “I’m Gonna Be,” but she is walking hundreds of miles, thousands one...
'Smart warheads' of cancer: Experts' excitement for treatment approach grows
Becker’s Hospital Review· 5 days agoCancer experts are increasingly optimistic about the potential for antibody-drug conjugates to become a standard treatment approach. The therapies involve attaching chemotherapy to an antibody ...
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological...
Benzinga· 2 days agoHONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 1 day agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
FDA Approves Imetelstat for Rare Low-Risk Blood Cancer
Medscape· 2 days agoThe approval for the first-in-class agent is "potentially practice changing" given the lack of treatment options for transfusion-dependent lower-risk MDS patients.
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 6 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...